| Trial ID: | L1695 |
| Source ID: | NCT06727409
|
| Associated Drug: |
Finerenone
|
| Title: |
Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i As Triple Therapy with Type 2 Diabetes and Chronic Kidney Disease
|
| Acronym: |
RAiSiN
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Patients with Type 2 Diabetes
|
| Interventions: |
DRUG: Finerenone
|
| Outcome Measures: |
Primary: Change in urine albumin creatinine ratio (uACR), urine ACR between baseline and end of study (26 weeks), 26 weeks | Secondary: Change in estimated glomerular filtration rate (eGFR), eGFR calculated from plasma creatinine from baseline to end of study in ml/min/1.73m2, 26 weeks|Change in potassium, Change in plasma potassium (mmol/l) from baseline to end of study, 26 weeks|Change in blood pressure, Change in systolic and diastolic blood pressure (mmHg) from baseline to end of study, 26 weeks|Change in heath related quality of life, change in HRQoL from baseline to end of study using EQ5D, 26 weeks|Change in body weight, Change in body weight (kg) from baseline to end of study, 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: Chinese University of Hong Kong
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
82
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-12-12
|
| Completion Date: |
2026-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-05
|
| Locations: |
3M, Diabetes and Endocrine Research Center, Hong Kong, Hong Kong
|
| URL: |
https://clinicaltrials.gov/show/NCT06727409
|
